NTM Lung Disease: What Aspergillosis Patients Need to Know

Audience: Patients living with chronic pulmonary aspergillosis (CPA), ABPA, or post-TB lung disease

Part 1: What is NTM Lung Disease?

Nontuberculous mycobacteria (NTM) are environmental organisms related to the tuberculosis (TB) bacteria. Found in soil, household water systems, and plumbing fixtures, NTM can cause chronic lung infections in people with damaged or weakened lungs. Unlike TB, NTM is not contagious.

NTM thrives in individuals with bronchiectasis, cavities, or chronic inflammation—conditions common in aspergillosis patients.

Part 2: 🌬️ How Do People Get Infected with NTM?

✅ The key source: Environment, not people

NTM are common in:

• Soil

• Household water systems

• Showerheads and taps

• Hot tubs

• Natural water (lakes, rivers)

When these bacteria become aerosolised (turned into a fine mist), they can be inhaled — especially during:

• Showering or bathing

• Using hot tubs or jacuzzis

• Gardening or digging in soil

• Running taps or using power tools that spray water

---

🫁 Who Is Most at Risk?

While many people breathe in NTM without any illness, infection is more likely if you have:

• Damaged lungs (e.g. bronchiectasis, COPD, prior TB, CPA)

• Weakened immunity

• Genetic conditions like cystic fibrosis

---

⚠️ NTM Is Not Contagious

• It does not spread from person to person like tuberculosis.

• You can’t catch it by sharing a room, hugging, or coughing near someone with NTM lung disease.

Part 3: Why Aspergillosis Patients Are at Risk

• Structural lung damage (e.g., bronchiectasis, cavities)
• Frequent use of steroids or antibiotics
• Impaired mucociliary clearance

These factors make the lungs more susceptible to NTM colonization and infection. Studies show 10–20% of CPA patients may also have NTM.

🧫 Epidemiology

• Increasing globally, especially in developed countries
• More common in older adults, particularly slender women over 50
• Also common in cystic fibrosis, COPD, prior TB

📋 Symptoms

• Chronic cough
• Fatigue
• Weight loss
• Low-grade fever
• Night sweats
• Hemoptysis

🧪 Diagnosis

Requires clinical, radiographic, and microbiologic evidence:

• Consistent symptoms
• CT scan showing nodules, cavities, or bronchiectasis
• Positive cultures: 2 sputum or 1 BAL or biopsy + culture

Part 4: Similar to Aspergillosis

NTM symptoms often mimic CPA, asthma, or bronchitis, leading to delayed diagnosis.

Part 5: 📈 Is It a Recent Threat?

• ✅ Increasing Incidence: From 2–3/100,000 in 1980s to 15–40+/100,000 today
• 📍 Hotspots: Southeast US, Japan, Brazil, Australia

🔍 Why Is It Emerging?

1. Aging population with chronic lung disease
2. Better detection with CT and cultures
3. More exposure to plumbing aerosols
4. Drug resistance (especially M. abscessus)

🚨 Public Health Impact

NTM is under-reported, often missed, and difficult to treat. The burden is rising.

Part 6: 🔎 Why Cases Are Missed

• Symptoms overlap with COPD, TB, ABPA
• Mycobacterial cultures not routinely ordered
• CT scans may be misread or misinterpreted

🩺 Missed Opportunities

📢 Improving Awareness

• New guidelines by ATS, ERS, IDSA
• Dedicated NTM/bronchiectasis clinics emerging
• Multidisciplinary teamwork encouraged

📊 Summary Table – current research

Species	Key Drugs	Imaging Pattern	Trials
MAC	Azithro + Ethambutol + Rifampin	Nodular / cavitary	CONVERT, SPR720
M. kansasii	Rifampin + INH + Ethambutol	Fibrocavitary	Historical
M. abscessus	IV Amikacin + Macrolides	Bronchiectasis + nodules	OPTIMA, NIX-NTM

FAQs

Q: Is NTM contagious?
A: No, NTM is not spread person-to-person like TB.

Q: Can I stop treatment early?
A: Only if your specialist advises, and usually not until your sputum cultures are negative for 12 months.

🛣️ The Patient Journey
Before diagnosis: Confusion and frustration
Diagnosis: Relief mixed with fear
Treatment phase: Long, with side effects
Post-treatment: Ongoing monitoring, lifestyle adjustments

💊 Treatment: What to Expect

NTM treatment is often long-term — typically lasting 12 to 18 months, and in some cases longer. It involves taking several antibiotics at once, depending on the NTM species. The goal is to achieve negative sputum cultures and reduce symptoms while preserving lung function.

Common medications: macrolides (azithromycin or clarithromycin), ethambutol, rifampin, and sometimes injectable antibiotics like amikacin.

Common side effects:

Nausea and vomiting — especially during the first few weeks
Fatigue and loss of appetite — can persist throughout treatment
Hearing loss — from amikacin; often requires audiology monitoring
Vision disturbances — from ethambutol; patients may need regular eye exams
Liver inflammation — elevated liver enzymes from rifampin or clarithromycin
Drug interactions — multiple antibiotics can conflict with other medications

Why persevere? Because untreated or undertreated NTM can lead to worsening lung damage, increased breathlessness, and further infections. Completing treatment can stop disease progression, reduce symptoms, and restore quality of life.

“I was on 13 pills a day at one point. My appetite was gone, and I was constantly exhausted. But I pushed through because I didn’t want to lose any more lung function.”
“Even though the side effects were tough, I knew stopping early might mean starting all over again — or worse.”

💬 Patient Quotes
“I had never heard of NTM. Suddenly I had to understand sputum cultures, drug combinations, and whether I’d lose my hearing from amikacin.”
“I felt like I had the flu every day for a year. People thought I was exaggerating — but this illness is invisible.”
“I finished treatment and stayed clear for 6 months. Then the cough came back and it was a different strain. I had to start all over.”

 What Patients Can Do
Ask your doctor about NTM if you have chronic cough or CPA flare
Avoid hot tubs, humidifiers, and soil exposure
Use sterile water in nebulizers
Join support groups for shared learning

Resources & Testimonials

• NTM Info & Research
• Aspergillosis.org
• Asthma & Lung UK
• Inspire NTM and Aspergillosis communities

✨ Final Thought

NTM lung disease may be a hidden complication for aspergillosis patients. But with early detection, specialist care, and support, you can manage it and protect your lung health.

🔚 Summary

NTM lung infections are a growing challenge for people with chronic lung disease, including those with aspergillosis. In the UK, recent studies suggest a prevalence of around 6–7 per 100,000 in the general population, and nearly 28 per 100,000 among those with chronic respiratory disease. This makes it as common—or more common—than tuberculosis in certain groups. While incidence may have declined in primary care settings, detection has likely shifted to hospitals and specialist clinics due to better awareness and diagnostics.

Though not fast-spreading, NTM infections can be progressive and difficult to treat. Recognising symptoms early, accessing testing, and receiving care from a multidisciplinary team are key to avoiding long-term damage and improving outcomes. Stay informed and proactive — NTM may be rare, but for some, it’s a life-altering diagnosis that needs prompt attention.

Path: Start » Living with Aspergillosis » NTM Lung Disease: What Aspergillosis Patients Need to Know